A conversation withMarkus Pimpl, Partners Group
Eltifs – the probability that there will be mishaps is high
Given the hype surrounding Eltifs, Markus Pimpl from Partners Group in Switzerland considers the likelihood of problems arising to be high. He argues that many asset managers lack the necessary expertise in private equity and private markets.
Frankfurt, November 29, 2024, 4:07: Uhr
Markus Pimpl, Partners Group
Source: Partners Group
BZ+
Jetzt weiterlesen mit BZ+
4 Wochen für nur 1 € testen
Zugang zu allen Premium-Artikeln
Flexible Laufzeit, monatlich kündbar.
Zugang zu allen Premium-Artikeln
Flexible Laufzeit, monatlich kündbar.
Themen des Artikels
Aus dem Ressort
Nürnberger posts losses and slashes dividend
Nürnberger Versicherung has posted the biggest consolidated loss in its corporate history, going 77 million euros into the red. It has drastically cut back on the upcoming dividend payout.
Plans to ramp up deep sea mining activities
Deep-sea mining could alleviate or even eliminate the forecast needed for the transition to a net-zero world. Consultants Roland Berger have conducted a study on industry plans for commercial production.
Bigger scale ambitions are needed
The fact that four universities in the Rhine-Main region are joining forces to strengthen the regional start-up scene is a nice idea. However, a look at the numbers by national and international comparison shows that more ambition is needed.
Germany losing ground in high tech
China and India are increasingly gaining a foothold in cutting-edge technology, and catching up with the industrialised countries. A UN Trade and Development (Unctad) study looks at how AI is likely to reshape the global economy.
Gerresheimer's multi-billion euro takeover might fall through
Gerresheimer's stock plummeted last Friday in response to KKR's withdrawal from the consortium of bidders for the pharmaceutical packaging company.
Bayer Pharma has six „blockbuster candidates“ at the start
Stefan Oelrich, Member of Bayer's Board of Management and Head of the Pharmaceuticals Division, is confident about the development pipeline. As one important patent expires, he points to a range of new products that will generate big sales.